Clinical trial · Interventional
Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis
Comparison of Triamcinolone With Pentoxifylline and Vitamin- E Efficacy in the Treatment of Stage 2 and 3 Oral Submucous Fibrosis: A Clinical Trial
NCT05660694CI-TRIAL-00062819completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To compare the efficacy of Triamcinolone with Pentoxifylline and Vitamin E in patients with stage two and three oral submucous fibrosis.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Submucosa Fibrosis | — | UNRESOLVED | — |
| Pentoxifylline | — | UNRESOLVED | — |
| Triamcinolone | — | UNRESOLVED | — |
| Tumor | Neoplasm | ALIAS | 0.90 |
| Vitamin E | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pentoxifylline with Vitamin E | Drug | — | UNRESOLVED |
| Triamcinolone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group 1: Triamcinolone
- description
- Injection steroid Triamcinolone 400mg with lidocaine 1:1 was given twice a week for 4 weeks in bi-lateral buccal mucosa in multiple sites
- interventionNames
- Drug: Triamcinolone
- type
- EXPERIMENTAL
- label
- Group 2: Pentoxifylline with Vitamin E
- description
- Pentoxifylline 40mg twice a day along with vitamin E supplement one tablet per day for 4 weeks
- interventionNames
- Drug: Pentoxifylline with Vitamin E
Primary outcomes (2)
- measure
- Group 1: Triamcinolone measuring mouth opening using calibrated Vernier Caliper
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with clinically diagnosed OSMF who have not undergone any treatment of OSMF in past * Patients willing to quit their tobacco chewing habit, gutkha areca nut smoking * Patients who are ready to attend regular follow-ups Exclusion Criteria: * Patients who have undergone any treatment for OSF in past * Patients with any evidence of cardiac, gastrointestinal, kidney, metabolic disorders, pregnant and lactating women's * Patients with any co-existing disorder of the orofacial region other than OSF which may interfere with the study protocol
References
Publications (0)
Data not yet available
No reference posted for this study.